To receive Email alerts, click here.

GenVec To Present at the 12th Annual BIO CEO & Investor Conference

02/01/10

GenVec Announces Registered Offering of $28 Million in Common Stock and Warrants

01/27/10

Data from TNFerade™ Esophageal Cancer Study Presented at 2010 ASCO Gastrointestinal Cancer Symposium

01/22/10

GenVec Enters Collaboration on Hearing Loss Treatments with Leading Global Pharmaceutical Company

01/19/10

Key Event Occurs in GenVec's PACT Trial

01/15/10

GenVec Regains Compliance With NASDAQ Listing Requirements

01/07/10

GenVec To Present at Biotech Showcase 2010

01/05/10

GenVec Announces Third Quarter 2009 Financial Results

11/05/09

GenVec Signs New Contract To Support HIV and Influenza Vaccine Development

11/05/09

FDA Grants Orphan Drug Designation for TNFerade™

11/04/09

GenVec To Present at Merriman Curhan Ford's Investor Summit 2009

11/03/09

GenVec Announces Third Quarter 2009 Results Conference Call

10/28/09

GenVec To Present at the BIO Investor Forum

10/22/09

GenVec Receives National Cancer Institute Grant to Expand Cancer Program

09/30/09

GenVec Receives Fourth-Year Funding from NIAID for HIV Vaccine Contract

09/24/09

GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance

09/16/09

GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants

08/27/09

GenVec Receives An Approximately $2.5 Million Grant To Support Novel Cell Line Development

08/25/09